Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | CML during pregnancy: implications and considerations for treatment

Elisabetta Abruzzese • 8 Sep 2023
SOHO 2023
Chronic Myeloid Leukemia Leukemia Bosutinib Dasatinib Imatinib Interferon Nilotinib Ponatinib

Elisabetta Abruzzese, MD, PhD, S. Eugenio University Hospital, Rome, Italy, discusses the implications and challenges of having chronic myeloid leukemia (CML) during pregnancy, as well as treatment options available. Dr Abruzzese highlights reasons why certain tyrosine kinase inhibitors (TKIs) should not be used during pregnancy, and summarizes registries which have been implemented to collect information for patients. Dr Abruzzese also discusses agents which may be administered once the placenta has formed, including nilotinib, interferon and imatinib, and concludes by discussing ongoing challenges in this space. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elisabetta Abruzzese

5:18
Investigating the outcomes of children born to patients with CML
Elisabetta Abruzzese • 11 Dec 2023
4:32
Patients with Ph+ CML entering TFR in pregnancy: a sub-analysis of the Italy TFR registry
Elisabetta Abruzzese • 11 Dec 2023
5:35
Situations that may arise with CML during pregnancy & management strategies
Elisabetta Abruzzese • 8 Sep 2023
1:11
The value of using personalized approaches when treating patients with MF
Elisabetta Abruzzese • 24 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals